8-K - Aptose Biosciences Inc. | StockGist

AI Analysis

AI-generated analysis. Always verify with the original filing.

Aptose Biosciences Inc. and Dr. William Rice, its Chairman, President and Chief Executive Officer, entered into the First Amendment to the Second Amended and Restated Employment Agreement effective March 12, 2026. The amendment confirms no deferred compensation plan was created or benefits earned and that Dr. Rice is solely responsible for related taxes, penalties and interest.

Key Takeaways

1Aptose Biosciences Inc. and Dr. William Rice entered First Amendment effective March 12, 2026, amending Sections 4.3, 15 and Schedule A of April 29, 2024 agreement.

2Confirms no deferred compensation benefits owed to Dr. Rice under the agreement or prior agreements.

3Dr. Rice solely responsible for individual taxes, penalties and interest on benefits; indemnifies company for related liabilities.

Current Report Details

Event Type

Material Agreement

Exhibits Only

Disclosure

Mandatory

Variant

8-K

Items Reported

1.01

Entry into a Material Definitive Agreement Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compens

Material Agreement

Source Document

9.01

. Financial Statements and Exhibits (d) Exhibits Exhibit Number Description 10.1 First Amendment 104 Cover Page Interactive Data File (embedded within the Inlin

Exhibits Only

Executive & Director Changes

Dr. William Rice

Chairman, President and Chief Executive Officer

First Amendment to Second Amended and Restated Employment Agreement

Effective: 2026-03-12

Exhibits (2)

10.1

EX-10.1

8-K